{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:08:04Z","timestamp":1774566484987,"version":"3.50.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Guangdong Provincial Department of Finance Project","award":["KS0120220271"],"award-info":[{"award-number":["KS0120220271"]}]},{"name":"Guangdong Provincial Department of Finance Project","award":["KS0120220272"],"award-info":[{"award-number":["KS0120220272"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Apalutamide is a generation androgen antagonist for the treatment of metastatic hormone sensitive prostate cancer and non-metastatic castration resistant prostate cancer. Skin adverse reactions caused by apalutamide are mostly rashes and maculopapules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>There are a few reports about exfoliative dermatitis caused by apalutamide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Severe exfoliative dermatitis induced by apalutamide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Gamma globulin, cefoperazone sulbactam sodium, albumin, ebastine, loratadine, hydrocortisone cream, and 3% boric acid lotion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Whole-body skin was red, without exudation, and with a small amount of desquamation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>The incidence of exfoliative dermatitis due to apalutamide is low but severe, and if a serious adverse skin reaction is suspected, apalutamide needs to be discontinued immediately and treated accordingly.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000047428","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:00:29Z","timestamp":1771005629000},"page":"e47428","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Severe exfoliative dermatitis induced by apalutamide in a mHSPC patient: A case report"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6286-5082","authenticated-orcid":false,"given":"Hanzhong","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Urology, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhong","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Urology, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiumin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260216","first-page":"352","article-title":"Associations between \u201cCancer Risk,\u201d \u201cInflammation\u201d and \u201cMetabolic Syndrome\u201d: a scoping review.","volume":"13","author":"Vitale","year":"2024","journal-title":"Biology (Basel)"},{"issue":"Pt 3","key":"R2-20260216","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.semcancer.2021.09.007","article-title":"Microbiota and prostate cancer.","volume":"86","author":"Rizzo","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R3-20260216","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study.","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"R4-20260216","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.euo.2024.11.005","article-title":"Apalutamide in metastatic castration-sensitive prostate cancer: results from the multicenter real-world ARON-3 study.","volume":"8","author":"Santoni","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"R5-20260216","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/1346-8138.16972","article-title":"Characteristics of mild and severe apalutamide-related cutaneous adverse events in patients with prostate cancer: a review of the literature.","volume":"51","author":"Katsuta","year":"2024","journal-title":"J Dermatol"},{"key":"R6-20260216","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1111\/1346-8138.15510","article-title":"Fatal case of toxic epidermal necrolysis due to apalutamide used as a novel prostate cancer drug.","volume":"47","author":"Endo","year":"2020","journal-title":"J Dermatol"},{"key":"R7-20260216","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cia2.12138","article-title":"A case of toxic epidermal necrolysis associated with apalutamide administration.","volume":"3","author":"Sagawa","year":"2020","journal-title":"J Cutaneous Immunol Allergy"},{"key":"R8-20260216","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/cod.14024","article-title":"The first case of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by apalutamide, a novel oral androgen receptor antagonist.","volume":"86","author":"Ducharme","year":"2022","journal-title":"Contact Dermatitis"},{"key":"R9-20260216","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4009\/jsdt.55.29","article-title":"A case of apalutamide\u2013induced toxic epidermal necrolysis that was treated with plasma exchange.","volume":"55","author":"Oda","year":"2022","journal-title":"Nihon Toseki Igakkai Zasshi"},{"key":"R10-20260216","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1111\/1346-8138.16248","article-title":"Plasmapheresis as a promising treatment option in apalutamide-associated toxic epidermal necrolysis.","volume":"49","author":"Miyagawa","year":"2022","journal-title":"J Dermatol"},{"key":"R11-20260216","doi-asserted-by":"crossref","first-page":"adv00723","DOI":"10.2340\/actadv.v102.2243","article-title":"Toxic epidermal necrolysis caused by apalutamide: a case report of treatment using etanercept with conventional steroid therapy.","volume":"102","author":"Osawa","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"R12-20260216","doi-asserted-by":"crossref","first-page":"1291564","DOI":"10.3389\/fimmu.2023.1291564","article-title":"Case report: apalutamide-induced severe lethal cutaneous adverse effects in China.","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"R13-20260216","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12894-020-00689-0","article-title":"Skin rash following administration of apalutamide in Japanese patients with advanced prostate cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.","volume":"20","author":"Uemura","year":"2020","journal-title":"BMC Urol"},{"key":"R14-20260216","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1021\/acs.chemrestox.9b00247","article-title":"Enzalutamide and apalutamide: in vitro chemical reactivity studies and activity in a mouse drug allergy model.","volume":"33","author":"Ji","year":"2020","journal-title":"Chem Res Toxicol"},{"key":"R15-20260216","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/iju5.12331","article-title":"Apalutamide-associated skin rash in patients with prostate cancer: histological evaluation by skin biopsy.","volume":"4","author":"Tohi","year":"2021","journal-title":"IJU Case Rep"},{"key":"R16-20260216","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.21873\/anticanres.15682","article-title":"Low body weight as a risk factor for apalutamide-related cutaneous adverse events.","volume":"42","author":"Katsuta","year":"2022","journal-title":"Anticancer Res"},{"key":"R17-20260216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0019-5154.48976","article-title":"Erythroderma: review of a potentially life-threatening dermatosis.","volume":"54","author":"Okoduwa","year":"2009","journal-title":"Indian J Dermatol"},{"key":"R18-20260216","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1272\/jnms.JNMS.2022_89-503","article-title":"Maculopapular drug eruption caused by apalutamide: case report and review of the literature.","volume":"89","author":"Katayama","year":"2022","journal-title":"J Nippon Med Sch"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:02:00Z","timestamp":1771257720000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047428","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"2025-06-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}